Recurrent Pregnancy Loss in Varanasi: Causes, Diagnosis & Evidence-Based Treatment

Recurrent pregnancy loss is clinically defined as two or more consecutive pregnancy losses occurring before 20 weeks of gestation. The European Society of Human Reproduction and Embryology (ESHRE) updated its definition in 2023 to include losses confirmed by ultrasound or histopathology — not just clinically symptomatic miscarriages. This matters because many Varanasi women experience early biochemical losses that are dismissed as 'late periods' and never counted or investigated.

RPL is distinct from infertility. Many women with RPL conceive relatively easily but cannot sustain the pregnancy beyond a certain gestational window. This distinction is clinically important because the investigations and treatment pathways are entirely different from those used for difficulty conceiving.

For Varanasi couples, particularly those in densely populated residential areas like Mahmoorganj or Bhelupur, the challenge is finding a structured pathway that moves beyond reassurance toward systematic evaluation. HomeIVF's RPL programme begins with a thorough case history — documenting each loss, gestational age, symptoms, any products-of-conception testing, and prior treatments — before a single investigation is ordered. This prevents unnecessary repeat testing and ensures every finding is interpreted in clinical context.

Understanding why RPL happens is the foundation of treating it effectively. The causes are broadly categorised into genetic, anatomical, immunological, thrombophilic, endocrine, and unexplained — and in many Varanasi patients, more than one factor contributes simultaneously.

Genetic factors are the most common single cause. Chromosomal abnormalities in the embryo — most often aneuploidies like trisomy 16 or monosomy X — account for up to 60% of first-trimester losses. Parental chromosomal rearrangements, such as balanced translocations, account for a smaller but clinically significant proportion and are entirely heritable.

Anatomical causes include uterine septum, submucosal fibroids, intrauterine adhesions (Asherman's syndrome), and bicornuate or arcuate uterus. These structural issues can interfere with implantation or foetal blood supply. In Varanasi, many women with undiagnosed uterine septa have undergone multiple losses before receiving a 3D ultrasound — a diagnostic step that is standard in HomeIVF's protocol.

Immunological causes — particularly antiphospholipid syndrome (APS) — are among the most treatable. APS triggers abnormal clotting in placental vessels and is diagnosed through specific antibody panels. Endocrine causes include poorly controlled thyroid disease, hyperprolactinaemia, and uncontrolled diabetes. All of these are prevalent in the Varanasi population and are thoroughly screened in the HomeIVF RPL panel.

Recurrent pregnancy loss does not always present dramatically. Recognising the pattern early allows couples in Varanasi to seek structured evaluation rather than waiting for a third or fourth loss.

The most recognisable symptom is vaginal bleeding during early pregnancy — often between 6 and 12 weeks — sometimes accompanied by cramping, passage of tissue, or a sudden disappearance of pregnancy symptoms like nausea and breast tenderness. However, in silent or missed miscarriages, the foetus may stop developing without any bleeding, discovered only at a routine scan.

Beyond physical symptoms, women with RPL often report a persistent anxiety during the first trimester, a heightened awareness of any pelvic sensation, and significant psychological distress that affects daily functioning. For women living in localities like Lanka or Sigra — where hectic urban routines intersect with family expectations — this psychological burden is real and clinically significant.

Red flags that warrant immediate RPL evaluation include: two or more losses at any gestational age, a prior loss at or beyond 10 weeks (which is less likely to be purely chromosomal and more likely to involve immunological or anatomical factors), a family history of clotting disorders, and any prior diagnosis of PCOS, thyroid disease, or uterine abnormality. HomeIVF's intake questionnaire is specifically designed to capture these signals.

A thorough RPL investigation is not a single blood test — it is a coordinated panel of investigations interpreted together by experienced reproductive medicine specialists. The HomeIVF Medical Board has developed a stepwise RPL panel appropriate for the Varanasi patient population, incorporating both international guidelines and locally prevalent conditions.

The core workup includes: parental karyotyping (chromosomal analysis for both partners), a thrombophilia panel covering antiphospholipid antibodies (anticardiolipin IgG/IgM, lupus anticoagulant, anti-β2 glycoprotein), Factor V Leiden and prothrombin gene mutation where clinically indicated, thyroid function tests including TSH and anti-TPO antibodies, prolactin levels, fasting insulin and glucose (to screen for insulin resistance), and a complete blood count.

Uterine evaluation is equally critical. A saline infusion sonography (SIS) or 3D transvaginal ultrasound can detect intrauterine adhesions, polyps, septa, and submucosal fibroids that a standard 2D scan misses. Where indicated, hysteroscopy provides both diagnosis and same-session treatment of anatomical abnormalities.

For couples with unexplained RPL or recurrent embryo failures after IVF, preimplantation genetic testing for aneuploidies (PGT-A) is now offered as part of HomeIVF's advanced RPL protocol. All samples collected in Varanasi are processed at NABL-accredited partner laboratories, with results reviewed by the HomeIVF Medical Board before any treatment recommendations are made.

Treatment for recurrent pregnancy loss is cause-specific — which is precisely why the diagnostic phase is non-negotiable. Once a cause (or combination of causes) is identified, evidence-based treatment can dramatically improve live birth rates.

For antiphospholipid syndrome, the combination of low-dose aspirin and low-molecular-weight heparin (LMWH) during pregnancy has been shown to improve live birth rates from approximately 10% (untreated) to 70-80% in well-managed cases. This is one of the most impactful treatment interventions in reproductive medicine.

For women with thyroid autoimmunity or subclinical hypothyroidism, optimising TSH to below 2.5 mIU/L before conception and maintaining it throughout the first trimester significantly reduces miscarriage risk. Hormonal support with progesterone supplementation (vaginal or oral) is widely used in early pregnancy, and while its benefit in unexplained RPL is debated, it is well-tolerated and supported by PRISM trial data for women with early bleeding.

Anatomical abnormalities — particularly uterine septa — are corrected via hysteroscopic resection, a minimally invasive procedure with a short recovery time. Couples with parental chromosomal translocations benefit significantly from IVF with PGT-A, which selects chromosomally normal embryos before transfer, reducing miscarriage risk to that of the general population. HomeIVF coordinates all these treatment pathways with packages starting from ₹1.5 lakh for eligible Varanasi patients.

HomeIVF was built on a single insight: senior-specialist fertility care should not require patients to travel repeatedly to distant cities or navigate crowded hospital corridors. For Varanasi couples dealing with RPL — who are already emotionally exhausted — reducing logistical friction is a clinical priority, not a luxury.

Through HomeIVF's Varanasi programme, patients receive a virtual consultation with a specialist from the HomeIVF Medical Board who reviews their full history, orders a targeted investigation panel, and coordinates home sample collection through certified phlebotomists. Patients in Lanka, Sigra, and Mahmoorganj have all used this service without needing to visit a clinic for initial evaluation.

Following investigation, the Medical Board prepares a personalised RPL report — explaining findings in plain language, outlining treatment options with their evidence base, and recommending next steps. Prescriptions, monitoring schedules, and follow-up consultations are all managed digitally, with 24/7 query support via the HomeIVF app.

For interventions requiring in-person procedures — such as hysteroscopy or embryo transfer — HomeIVF works with a curated network of accredited partner clinics in Varanasi and the broader eastern UP region. Patients are never left to navigate this alone; a dedicated case coordinator manages the entire care journey from first consultation to post-procedure follow-up.

One of the most anxiety-provoking aspects of pregnancy after RPL is the period between clinical appointments — the days when a woman is at home, uncertain whether the pregnancy is progressing, and without immediate access to reassurance. HomeIVF's home monitoring programme is specifically designed to address this gap for Varanasi patients.

During the first trimester, home monitoring includes: serial quantitative β-hCG testing (with home blood draw), progesterone level checks at defined intervals, blood pressure monitoring for women on heparin or with hypertensive risk, and INR monitoring where indicated. All results feed directly into the patient's HomeIVF dashboard, where the Medical Board reviews them and responds within 24 hours.

For women in localities like Bhelupur or Sigra where travel to a diagnostic centre may require significant time, home phlebotomy eliminates a logistical barrier that can otherwise lead to delayed testing and missed clinical windows. Early detection of a falling hCG or inadequate progesterone rise allows timely dose adjustments that could make a meaningful difference to outcome.

Psychological support is integrated into the monitoring programme. RPL is associated with clinically significant anxiety, depression, and grief, and the HomeIVF platform connects patients with trained fertility counsellors who understand the specific emotional landscape of pregnancy after loss.

Varanasi is a city of contrasts. Highly educated, health-conscious couples coexist with deeply embedded beliefs about fertility — including the idea that repeated miscarriage is 'fate' or that investigations are unnecessary after a first or second loss. These beliefs, while understandable, delay evidence-based care and cost couples irreplaceable time.

A significant barrier is the fragmented nature of gynaecological care in the city. Many general gynaecologists in Varanasi are skilled in routine obstetrics but do not have subspeciality training in reproductive immunology, genetics, or advanced uterine evaluation. Patients with RPL frequently receive reassurance ('just try again') rather than investigation, resulting in further losses before a cause is identified.

Geographic concentration of specialist care in central areas — while couples in peripheral localities like Mahmoorganj or Lanka face long commutes — adds another layer of friction. Socioeconomic barriers, lack of awareness about investigations like PGT-A or thrombophilia panels, and limited insurance coverage for fertility workup all compound the problem.

HomeIVF removes these barriers systematically: virtual access to a specialist board, home sample collection, digital result delivery, transparent care pathways, and a medical team that communicates in plain language. For Varanasi couples who have suffered the grief of RPL, this means faster diagnosis, earlier intervention, and — most importantly — a higher chance of holding a healthy baby.